Page last updated: 2024-11-07

sk&f 94482

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID135156
CHEMBL ID4643501
SCHEMBL ID4607536
MeSH IDM0149174

Synonyms (20)

Synonym
86134-80-7
8v3s9m26de ,
sk&f 94482
skf 94482
3-cyclobutene-1,2-dione, 3-amino-4-((3-(3-(1-piperidinylmethyl)phenoxy)propyl)amino)-
unii-8v3s9m26de
skf-94482
bmy-25368
bmy 25368
3-amino-4-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]cyclobut-3-ene-1,2-dione
1-[3-[3-(piperidinomethyl)phenoxy]prop-1-ylamino]-2-amino-cyclobut-1-ene-3,4-dione
KSBYXRUNSLGUNE-UHFFFAOYSA-N ,
1-amino-2-[3-(3-piperidinomethylphenoxy)propylamino]-1-cyclobutene-3,4-dione
SCHEMBL4607536
DTXSID50235421
3-amino-4-((3-(3-(1-piperidinylmethyl)phenoxy)propyl)amino)-3-cyclobutene-1,2-dione
bdbm50543289
CHEMBL4643501 ,
PD161090
AKOS040745620

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Following BMY-25368 administration, hydrogen ion concentration was decreased and mean pH was higher than baseline values in a dose-response pattern."( Effects of a histamine type-2 receptor antagonist (BMY-25368) on gastric secretion in horses.
Dreyfuss, DJ; Orsini, JA; Spencer, PA; Uhlman, R; Vecchione, J, 1991
)
0.28
" The importance of the time of dosing of potent, long-acting H2 blockers for optimal suppression of intragastric acidity is unknown."( Is the time of dosing of a potent long-acting H2-receptor antagonist critical? Twenty-four-hour pH measurements with SKF-94482.
Merki, HS; Wilder-Smith, CH, 1991
)
0.28
"Evening dosing has become standard for H2 receptor antagonists, because available agents inhibit nocturnal basal acid secretion more effectively than daytime stimulated secretion."( Do H2 receptor antagonists have to be given at night? A study of the antisecretory profile of SKF 94482, a new H2 receptor antagonist which has a profound effect on daytime acidity.
Burget, DW; Chiverton, SG; Hunt, RH, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H2 receptorHomo sapiens (human)Ki0.01590.00062.197310.0000AID1661712
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1661706Antagonist activity at Gsalphas-coupled human H2R expressed in baculovirus infected Sf9 cells incubated for 60 mins in presence of histamine by GTPgammaS binding assay2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
Fluorescent H
AID1661712Binding affinity to human H2R expressing Sf9 cells incubated for 60 mins by microbeta scintillation counter method2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
Fluorescent H
AID1661708Selectivity index, ratio of Ki for human H3R expressed in baculovirus infected Sf9 cells to Ki for Gsalphas-coupled human H2R expressed in baculovirus infected Sf9 cells2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
Fluorescent H
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (50.00)18.7374
1990's2 (25.00)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.73 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (37.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (62.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]